Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer

NCT00798720 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT00798720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00798720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
October 31, 2012
Enrollment
18 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non small cell lung